Hemodynamic long-term results after medical and surgical therapy of hypertrophic cardiomyopathies

  • Benno Lösse
  • F. Loogen
  • H. D. Schulte
Conference paper


Nearly 30 years after the first modern descriptions of hypertrophic cardiomyopathy (10, 50), the ideal form of therapy, which should be low-risk and effective in all patients with this disease, has not yet been found. Most information was gathered in chronological order on surgical therapy and the application of beta-adrenergic blocking and calcium-antagonistic drugs. None of these therapy forms is causal. The primary effort is, therefore, directed at ameliorating the patient’s disabling symptoms, increasing their reduced exercise capacity, and prolonging life. Functional limitation is primarily caused by hemodynamic impairment and rhythm disturbances. Hemodynamic measurements, particularly when performed during exercise, are therefore a suitable method for comparing and quantifying the effectiveness of different forms of therapy.


Pulmonary Artery Pressure Hypertrophic Cardiomyopathy NYHA Class Hypertrophic Obstructive Cardiomyopathy Propranolol Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adelman AG, Wigle ED, Ranganathan N, Webb GD, Kidd BSL, Bigelow WG, Silver MD (1972) The clinical course in muscular subaortic stenosis: a retrospective and prospective study of 60 hemodynamically proved cases. Ann Intern Med 77: 515–524PubMedGoogle Scholar
  2. 2.
    Anderson DM, Raff GL, Ports TA, Brundage BH, Parmley WW, Chatterjee K (1984) Hÿpertrophic obstructive cardiomyopathy. Effects of acute and chronic verapamil treatment on left ventricular systolic and diastolic function. Br Heart J 51: 523–529PubMedCrossRefGoogle Scholar
  3. 3.
    Beahrs MM, Tajik AJ, Seward JB, Giuliani ER, McGoon DC (1983) Hypertrophic obstructive cardiomyopathy: Ten-to 21-year follow-up after partial septal myectomy. Am J Cardiol 51: 1160–1166PubMedCrossRefGoogle Scholar
  4. 4.
    Betocchi S, Bonow RO, Bacharach SL, Rosing DR, Maron BJ, Green MV (1986) Isovolumic relaxation period in hypertrophic cardiomyopathy: Assessment by radionuclide angiography. J Am Coll Cardiol 7: 74–81Google Scholar
  5. 5.
    Bigelow W, Trimble AS, Wigle ED, Adelman AG, Felderhof C (1974) The treatment of muscular subaortic stenosis. J Thorac Cardiovasc Surg 68: 384–391PubMedGoogle Scholar
  6. 6.
    Bonow RO (1985) Effects of calcium-channel blocking agents on left ventricular diastolic function in hypertrophic cardiomyopathy and in coronary artery disease. Am J Cardiol 55: 172B - 178BPubMedCrossRefGoogle Scholar
  7. 7.
    Bonow RO, Rosing DR, Bacharach SL, Green MV, Kent KM, Lipson LC, Maron BJ, Leon MB, Epstein SE (1981) Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation 64: 787–796PubMedCrossRefGoogle Scholar
  8. 8.
    Bonow RO, Rosing DR, Epstein SE (1983) The acute and chronic effects of verapamil on left ventricular function in patients with hypertrophic cardiomyopathy. Eur Heart J 4, Suppl F: 5765Google Scholar
  9. 9.
    Borer JS, Bacharach SL, Green MV, Kent KM, Rosing DR, Seides SF, Morrow AG, Epstein SE (1979) Effect of septal myotomy and myectomy on left ventricular systolic function at rest and during exercise in patients with IHSS. Circulation 60, Suppl I: 82–87Google Scholar
  10. 10.
    Brock RC (1957) Functional obstruction of the left ventricle, Guys Hosp Rep 106: 221–238PubMedGoogle Scholar
  11. 11.
    Edwards RHT, Kristinsson A, Warrell DA, Goodwin JF (1970) Effects of propranolol on response to exercise in hypertrophic obstructive cardiomyopathy. Br Heart J 32: 219–225PubMedCrossRefGoogle Scholar
  12. 12.
    Flamm MD, Harrison DC, Hancock EW (1968) Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol. Circulation 38: 846–858Google Scholar
  13. 13.
    Frank MJ, Abdulla AM, Canedo MI, Saylors RE (1978) Long-term medical management of hypertrophic obstructive cardiomyopathy. Am J Cardiol 42: 993–1001PubMedCrossRefGoogle Scholar
  14. 14.
    Frank MJ, Abdulla AM, Watkins LO, Prisant L, Stefadouros MA (1983) Long-term medical management of hypertrophic cardiomyopathy: usefulness of propranolol. Eur Heart J 4, Suppl F: 155–164Google Scholar
  15. 15.
    Haberer T, Hess OM, Jenni R, Krayenbühl HP (1983) Hypertrophe obstruktive Kardiomyopathie: Spontanverlauf im Vergleich zur Langzeittherapie mit Propranolol and Verapamil. Z Kardiol 72: 487–493Google Scholar
  16. 16.
    Hanrath P, Mathey DG, Kremer P, Sonntag F, Bleifeld W (1980) Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy. Am J Cardiol 45: 1258–1264PubMedCrossRefGoogle Scholar
  17. 17.
    Hanrath P, Schlüter M, Sonntag F, Diemert J, Bleifeld W (1983) Influence of verapamil therapy on left ventricular performance at rest and during exercise in hypertrophic cardiomyopathy. Am J Cardiol 52: 544–548PubMedCrossRefGoogle Scholar
  18. 18.
    Harrison DC, Braunwald E, Glick G, Mason DT, Chidsey CA, Ross J Jr (1964) Effects of beta adrenergic blockade on the circulation, with particular reference to observation in patients with hypertrophic subaortic stenosis. Circulation 29: 84–98PubMedGoogle Scholar
  19. 19.
    Hess OM, Grimm J, Krayenbuehl HP (1983) Diastolic function in hypertrophic cardiomyopathy: effects of propranolol and verapamil on diastolic stiffness. Eur Heart J 4, Suppl F: 47–56Google Scholar
  20. 20.
    Kaltenbach M, Hopf R (1985) Treatment of hypertrophic cardiomyopathy: relation to pathological mechanisms. J Mol Cell Cardiol 17: 59–68PubMedCrossRefGoogle Scholar
  21. 21.
    Kaltenbach M, Hopf R, Kober G, Bussmann WD, Keller M, Petersen Y (1979) Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J 42: 35–42PubMedCrossRefGoogle Scholar
  22. 22.
    Kober G, Schmidt-Moritz A, Hopf R, Kaltenbach M (1983) Long-term treatment of hypertrophie obstructive cardiomyopathy — usefulness of verapamil. Eur Heart J 4, Suppl F: 165–174Google Scholar
  23. 23.
    Kuhn H, Gietzen F, Mercier J, Lösse B, Köhler E, Schulte HD, Bircks W, Loogen F (1983) Untersuchungen zur Klinik, zum Verlauf und zur Prognose der hypertrophischen Kardiomyopathie. Z Kardiol 72: 83–98PubMedGoogle Scholar
  24. 24.
    Kuhn H, Loogen F (1978) Die Anwendung von Beta-Rezeptorenblockern bei hypertrophischer obstruktiver Kardiomyopathie ( HOCM ). Internist 19: 527–531Google Scholar
  25. 25.
    Kuhn H, Thelen U, Leuner C, Köhler E, Bluschke V (1980) Langzeitbehandlung der hypertrophischen nicht obstruktiven Kardiomyopathie ( HNCM) mit Verapamil. Z Kardiol 69: 669–675Google Scholar
  26. 26.
    von der Lohe E, Müller-Haake C, von Essen R, Effert S, Messmer BJ (1984) Septumresektion bei hypertropher obstruktiver Kardiomyopathie: Langzeitergebnisse bei 33 Patienten. Dtsch med Wschr 109: 1749–1753PubMedCrossRefGoogle Scholar
  27. 27.
    Loogen F, Kuhn H, Gietzen F, Lösse B, Schulte HD, Bircks W (1983) Clinical course and prognosis of patients with typical and atypical hypertrophic obstructive and with hypertrophie non-obstructive cardiomyopathy. Eur Heart J 4, Suppl F: 145–153Google Scholar
  28. 28.
    Loogen F, Kuhn H, Krelhaus W (1978) Natural history of hypertrophic obstructive cardiomyopathy. In: Kaltenbach M, Loogen F, Olsen EGJ (eds) Cardiomyopathy and Myocardial Biopsy. Springer-Verlag, Berlin-Heidelberg—New York, pp 286–299CrossRefGoogle Scholar
  29. 29.
    Lösse B, Kuhn H, Krönert H, Rafflenbeul D, Kirschner P, Schulte HD, Loogen F (1980) Hämodynamische Auswirkungen konservativer und operativer Therapie bei hypertrophischer obstruktiver Kardiomyopathie. Z Kardiol 69: 470–477PubMedGoogle Scholar
  30. 30.
    Lösse B, Kuhn H, Loogen F (1982) Results of exercise testing in medically and surgically treated patients with hypertrophic cardiomyopathy. In: Kaltenbach M, Epstein SE (eds) Hypertrophie Cardiomyopathy; Springer-Verlag, Berlin—Heidelberg—New York, pp 251–260CrossRefGoogle Scholar
  31. 31.
    Lösse B, Kuhn H, Loogen F (1982) Klinische and hämodynamische Effekte von Verapamil bei hypertrophischer obstruktiver Kardiomyopathie. Z Kardiol 71: 813–819PubMedGoogle Scholar
  32. 32.
    Lösse B, Kuhn H, Loogen F, Schulte HD (1983) Exercise performance in hypertrophic cardiomyopathies. Eur Heart J 4, Suppl F: 197–208Google Scholar
  33. 33.
    Lösse B, Loogen F, Schulte HD (1984) Frühe and späte hämodynamische Veränderungen nach operativer Therapie der hypertrophischen obstruktiven Kardiomyopathie. Z Kardiol 73: 654–662PubMedGoogle Scholar
  34. 34.
    Maron BJ, Merrill WH, Freier PA, Kent KM, Epstein SE, Morrow AG (1978) Long-term clinical course and symptomatic status of patients after operation for hypertrophie subaortic stenosis. Circulation 57: 1205–1213PubMedGoogle Scholar
  35. 35.
    Oakley CM (1971) Hypertrophic obstructive cardiomyopathy — patterns of progression. In: Wolstenholme GEW, O’Connor M (eds) Hypertrophie Obstructive Cardiomyopathy. Ciba Foundation Symposium; Churchill, London, pp 9–29Google Scholar
  36. 36.
    Oakley CM (1975) Surgical correction of ASH. Circulation 51: 951–952PubMedGoogle Scholar
  37. 37.
    Powell WJ Jr, Whiting RB, Dinsmore RE, Sanders CA (1973) Symptomatic prognosis in patients with hypertrophie subaortic stenosis ( IHSS ). Am J Med 55: 15–24Google Scholar
  38. 38.
    Redwood DR, Goldstein RE, Hirshfeld J, Borer JS, Morganroth J, Morrow AG, Epstein SE (1979) Exercise performance after septal myotomy and myectomy in patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol 44: 215–220PubMedCrossRefGoogle Scholar
  39. 39.
    Rosing DR, Condit JR, Maron BJ, Kent KM, Leon MB, Bonow RO, Lipson LC, Epstein SE (1981) Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III: Effects of long-term administration. Am J Cardiol 48: 545–553Google Scholar
  40. 40.
    Rosing DR, Kent KM, Borer JS, Seides SF, Maron BJ, Epstein SE (1979) Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Circulation 60: 1201–1207Google Scholar
  41. 41.
    Rosing DR, Kent KM, Maron BJ, Epstein SE (1979) Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation 60: 1208–1213Google Scholar
  42. 42.
    Rothlin ME, Gobet D, Haberer T, Krayenbühl HP (1983) Surgical treatment versus medical treatment in hypertrophic obstructive cardiomyopathy. Eur Heart J 4, Suppl F: 215–223Google Scholar
  43. 43.
    Schmid P, Pavek P, Klein W (1979) Echokardiographische and hämodynamische Untersuchungen zur Beeinflussung der hypertrophischen obstruktiven Kardiomyopathie durch Verapamil. Z Kardiol 68: 89–92PubMedGoogle Scholar
  44. 44.
    Schulte HD, Bircks W, Körfer R, Kuhn H (1981) Surgical aspects of typical subaortic and atypical midventricular hypertrophie obstructive cardiomyopathy ( HOCM ). Thorac Cardiovasc Surg 29: 375–380Google Scholar
  45. 45.
    Shah PM, Adelman AG, Wigle ED, Gobel FL, Burchell HB, Hardarson T, Curiel R, De la Calzada C, Oakley CM, Goodwin JF (1974) The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy. Circ Res 34/35, Suppl II: 179–195Google Scholar
  46. 46.
    Spicer RL, Rocchini AP, Crowley DC, Rosenthal A (1984) Chronic verapamil therapy in pediatric and young adult patients with hypertrophic cardiomyopathy. Am J Cardiol 53: 1614–1619PubMedCrossRefGoogle Scholar
  47. 47.
    Stenson RE, Flamm MD Jr, Harrison DC, Hancock EW (1973) Hypertrophie subaortic stenosis: clinical and hemodynamic effects of long-term propranolol therapy. Am J Cardiol 31: 763–773PubMedCrossRefGoogle Scholar
  48. 48.
    Swanton RH, Brooksby IAB, Jenkins BS, Webb-Peploe MM (1977) Hemodynamic studies of fl blockade in hypertrophie obstructive cardiomyopathy. Eur J Cardiol 5 /4: 327–341PubMedGoogle Scholar
  49. 49.
    Tajik AJ, Giuliani GR, Weidman WH, Brandenburg RD, McGoon DC (1974) Idiopathic hypertrophic subaortic stenosis. Long-term surgical follow-up. Am J Cardiol 34: 815–822Google Scholar
  50. 50.
    Teare RD (1958) Asymmetrical hypertrophy of the heart in young adults. BR Heart J 20: 1–8PubMedCrossRefGoogle Scholar
  51. 51.
    Turina J, Jenni R, Krayenbuehl HP, Turina M, Rothlin M (1986) Echocardiographic findings late after myectomy in hypertrophic obstructive cadiomyopathy. Eur Heart J 7: 685–692PubMedGoogle Scholar
  52. 52.
    Wigle ED, Sasson Z, Handerson MA, Ruddy TD, Fulop J, Rakowski H, Williams WG (1985) Hypertrophie cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Progr Cardiovasc Dis 28: 1–8Google Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 1988

Authors and Affiliations

  • Benno Lösse
    • 1
    • 2
  • F. Loogen
    • 1
  • H. D. Schulte
    • 3
  1. 1.Dept. of Cardiology, Pneumology and AngiologyUniversity of DüsseldorfGermany
  2. 2.Abteilung für Kardiologie, Pneumologie und AngiologieMedizinische Klinik und Poliklinik der UniversitätDüsseldorfGermany
  3. 3.Dept. of Thoracic and Cardiovascular SurgeryUniversity of DüsseldorfGermany

Personalised recommendations